Menu

Blog

Jan 18, 2024

FDA Approves New CRISPR Gene-Editing Treatment

Posted by in categories: biotech/medical, genetics

The Food and Drug Administration approved the use of Casgevy, a CRISPR gene-editing therapy, for treating the serious blood disorder transfusion-dependent beta thalassemia—the second major approval for the emerging therapy.

Comments are closed.